ISSN print edition: 0366-6352 ISSN electronic edition: 1336-9075 Registr. No.: MK SR 9/7 Published monthly

Glutathione (GSH) conjugated Bi₂S₃ NPs as a promising radiosensitizer against glioblastoma cancer cells

Ke Wang, Abduladheem Turki Jalil, Marwan Mahmood Saleh, Sona Talaei, and Linlin Wang

Department of Neurosurgery, 3201 Hospital, HanZhong, China

E-mail: wanglinfmmu@sina.com

Received: 3 October 2022  Accepted: 13 November 2022

Abstract:

Glioblastoma is one of the serious cancer in the world that treatment methods of this tumor through conventional methods such as surgery and chemotherapeutics are challenging due to difficult accessibility and blood–brain barrier (BBB). Here, in order to have appropriate efficacy of glioblastoma treatment with radiotherapy we developed targeted nanoradiosensitizer, which can be a promising procedure in favor of decreasing dosage of radiation. In this study, bismuth sulfide (Bi₂S₃) as a radiosensitizer agent with high atomic number coated with bovine serum albumin, which introduced high chemical stability, nontoxicity, and biodegradability to synthesized nanoparticles. Glutathione is also employed in this designing as the BBB shuttle peptide. After characterization of this designing through the FeSEM, DLS, FTIR and XRD, whose efficacy of treatment on cancer cell line (U87) is accomplished through the MTT, apoptosis, ROS and calcein AM/PI in presence and absence of X-ray.

Keywords: X-ray; Glioblastoma; Radiotherapy; Radiosensitizer

Full paper is available at www.springerlink.com.

DOI: 10.1007/s11696-022-02592-4

Chemical Papers 77 (4) 1921–1928 (2023)